Cancer Gene Therapy Market Key Manufacturing Base and Competitors Growth Rate for 2017-2022Medgadget (blog)ReportsnReports.com has announced the addition of the Global Cancer Gene Therapy Industry 2017 Market Research Report published in July 2017 from… Continue reading
Deutsche WelleFood from labs for a sustainable future?Deutsche Welle… hundred times more efficient – and digital biology has the solution. By producing milk in vitro, we can make the process 10 to 100 times more energy-efficient. There are now a lot … Continue reading
Phys.Org |
Scientists bring back extinct horsepox virus in lab, raising important biosecurity questions
Phys.Org This fact raises questions about the limitations of regulations that are in place to monitor synthetic biological research, says Inglesby. “The researchers who did this work are reported to have gone through all appropriate national regulatory … |
EurekAlert (press release) |
Researchers describe novel reporter proteins for long term expression of therapeutic genes
EurekAlert (press release) In the article “Prolonged Expression of Secreted Enzymes in Dogs after Liver-Directed Delivery of Sleeping Beauty Transposons: Implications for Non-Viral Gene therapy of Systemic Disease,” Elena Aronovich et al. concluded that more research is needed … |
Reuters |
Novartis readies for FDA review of $1 billion CAR–T child cancer hope
Reuters They began with several molecules, but finally settled on one, called 4-1BB, because it seemed to prime the human immune system to attack blood cancer more aggressively than others. “Our first tests convinced us these T cells were special,” Campana … Novartis CAR–T safety in FDA spotlightpharmaphorum Novartis’ CAR–T Therapy for Pediatric Leukemia to Face FDA Advisory PanelAJMC.com Managed Markets Network |
Reuters |
Novartis readies for FDA review of $1 billion CAR–T child cancer hope
Reuters Campana’s 4-1BB is the key ingredient of the Swiss drugmaker’s therapy, which involves T cells being extracted from patients, genetically re-engineered, and then unleashed to kill leukemia cells growing out of control. Of 68 desperately ill children … Novartis CAR-T safety in FDA spotlight – Pharmaphorumpharmaphorum Novartis’ CAR–T Therapy for Pediatric Leukemia to Face FDA Advisory PanelAJMC.com Managed Markets Network UPDATE 1-FDA panel to focus on safety of Novartis gene therapy …Business Insider |
|
Novartis readies for FDA review of $1 bln CAR–T child cancer hope
Reuters “Our first tests convinced us these T cells were special,” Campana, now a scientist at the National University Cancer Institute in Singapore, told Reuters by email this week. “I had never seen any drug killing leukemic cells so rapidly and specifically.”. |